Novan (NOVNW) Other Gross PPE : $18.11 Mil (As of Mar. 2023)

View and export this data going back to 2018. Start your Free Trial

What is Novan Other Gross PPE?

Novan's Other Gross PPE for the quarter that ended in Mar. 2023 was $18.11 Mil.

Novan's quarterly Other Gross PPE increased from Sep. 2022 ($17.73 Mil) to Dec. 2022 ($18.07 Mil) and increased from Dec. 2022 ($18.07 Mil) to Mar. 2023 ($18.11 Mil).

Novan's annual Other Gross PPE increased from Dec. 2020 ($3.49 Mil) to Dec. 2021 ($15.22 Mil) and increased from Dec. 2021 ($15.22 Mil) to Dec. 2022 ($18.07 Mil).

Novan Other Gross PPE Historical Data

The historical data trend for Novan's Other Gross PPE can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Novan Other Gross PPE Chart

Novan Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Other Gross PPE

Get a 7-Day Free Trial

8.61

16.80

3.49

15.22

18.07

Novan Quarterly Data
	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23
Other Gross PPE	Get a 7-Day Free Trial															16.86	17.59	17.73	18.07	18.11

Novan Other Gross PPE Calculation

GuruFocus lists Land And Improvements, Buildings And Improvements, Machinery, Furniture, Equipment, Construction In Progress and Other Gross PPE under the "Gross Property, Plant and Equipment" section.

Novan Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Novan Inc (OTCPK:NOVNW) » Definitions » Other Gross PPE

Comparable Companies

Traded in Other Exchanges

N/A

Address

P.O. Box 64, Pittsboro, NC, USA, 27312

Website

https://www.novan.com

NVN Liquidation Inc Formerly Novan Inc is a dermatology company focused on developing and commercializing therapeutic products for skin diseases. It is developing SB206 as a topical prescription gel for the treatment of viral skin infections. The company's product portfolio includes; Wynzora Cream for the treatment of plaque psoriasis, Rhofade cream for the treatment of persistent facial erythema, Minolira tablets to treat inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients, Cloderm cream for the relief of the inflammatory and pruritic manifestations of corticosteroid-responsive dermatoses, Sitavig tablets for the treatment of recurrent herpes labialis in immunocompetent adults, and Nuvail nail solution for managing signs and symptoms of nail dystrophy.